1201903-02-7

Basic information

• Product Name: Ixazomib Impurity 1
• Synonyms: Ixazomib Impurity 1;2,5-dichloro-N-(2-(((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-2-oxoethyl)benzamide
• CAS NO: 1201903-02-7
• Molecular Formula: C₂₄H₃₃BCl₂N₂O₄
• Molecular Weight: 495.24682
• Mol File: 1201903-02-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: Dichloromethane; Chloroform; Methanol; Ethyl Acetate; DMSO
• CAS DataBase Reference: Ixazomib Impurity 1(CAS DataBase Reference)
• NIST Chemistry Reference: Ixazomib Impurity 1(1201903-02-7)
• EPA Substance Registry System: Ixazomib Impurity 1(1201903-02-7)

Safety Data

• Hazardous Substances Data: 1201903-02-7(Hazardous Substances Data)

Usage

Uses

2,5-Dichloro-N-[2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-2-oxoethyl]-benzamide is an intermediate used in the synthesis of Ixazomib (I942000), which is a proteasome inhibitor that acts by preventing cell growth in solid tumours. It is an anticancer agent that is used to treat patients with multiple myeloma and is potentially neurotoxic.

Upstream product

• 84110-34-9 2-(2-methylpropyl)-(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborole 
• 85167-14-2 (3aS,4S,6S,7aR)-2-[(1S)-1-chloro-3-methylbutyl]-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborole 
• 667403-46-5 2-[(2,5-dichlorobenzoyl)amino]acetic acid 
• 779357-85-6 (1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxabor-ol-2-yl]butan-1-amine hydrochloride 
• 18680-27-8 pinanediol 
• 1310383-72-2 (aR,3aS,4S,6S,7aR)-hexahydro-3a,8,8-trimethyl-α-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate 
• 50-79-3 2,5-dichlorobenzoic acid 
• 179324-86-8 (1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^2,6]decan-4-yl]butan-1-amine 
• 2905-61-5 2,5-dichlorobenzoyl chloride 

Downstream Products

• 1201903-03-8 Ν,Ν',Ν''-[boroxin-2,4,6-triyltris[[(1R)-3-methylbutane-1,1-diyl]imino(2-oxoethane-2,1-diyl)]]tris(2,5-dichlorobenzamide) 
• 1239908-20-3 2,2’-{2-[(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid 
• 1072833-77-2 Ixazomib 

Relevant articles and documents

Virtues of Volatility: A Facile Transesterification Approach to Boronic Acids

Boronic acids are an increasingly important compound class for many applications, including C-C bond formation reactions, medicinal chemistry, and diagnostics. The deprotection of boronic ester intermediates is frequently a problematic and inefficient step in boronic acid syntheses. We describe an approach that highly facilitates this transformation by leveraging the volatility of methylboronic acid and its diol esters. The method is performed under mild conditions, provides high yields, and eliminates cumbersome and problematic purification steps.

A PROCESS FOR THE PREPARATION OF IXAZOMIB CITRATE

The present invention relates to a process for the preparation of compound of formula (I), wherein, R1 and R2 are each independently hydroxy, alkoxy, aryloxy, or aralkoxy; or R1 and R2 together form a moiety derived from an alpha-hydroxy carboxylic acid compound or a beta-hydroxy carboxylic acid compound, wherein the atom attached to boron in each case is an oxygen atom; or R1 and R2 together form the boronate esters of boronic acid.

Preparation process method for boron-containing compound

The invention discloses a preparation method for a boron-containing compound MLN2238. The method for preparing the MLN2238, disclosed by the invention, comprises the steps of adopting a solid compound intermediate II, which is stable in properties and can be subjected to recrystallization and purification, as an intermediate node for quality control, carrying out recrystallization or pulping purification on the intermediate, and then, carrying out a next-step reaction, thereby obtaining the boron-containing compound MLN2238 with relatively high purity. The synthesis process route is free of special requirements on production equipment, the reaction conditions are mild, and all the raw materials are all marketable products, so that the process route is very applicable to industrial production.